Omeprazole absorption from a compounded transdermal formulation in healthy volunteers

Journal of the American Pharmacists Association

Volumn 45, Issue 4, 2005, Pages 473-478

  Haas, Curtis E ^a,b   Lin, Lydia ^d   Cloen, Denise ^d   Kufel, Thomas ^b   Moon, Richard ^a,c   Frerichs, Valerie ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^c Pharmacy Innovations   (United States)

^d Pharmacy Innovations ^*

Author keywords

Compounding; Omeprazole; Pharmacokinetics; Transdermal drug administration

Indexed keywords

OMEPRAZOLE; ANTIULCER AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; HALF LIFE TIME; HUMAN; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; TANDEM MASS SPECTROMETRY; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; GEL; INTRADERMAL DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MICROCAPSULE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SKIN; SKIN ABSORPTION; TIME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; CAPSULES; CHROMATOGRAPHY, LIQUID; FEMALE; GELS; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; OMEPRAZOLE; SKIN; SKIN ABSORPTION; TIME FACTORS;

EID: 33646898159     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544345054475603     Document Type: Article

References (19)

1. Quercia RA, Fan C, Liu X, Chow MS. Stability of omeprazole in an extemporaneously prepared oral liquid. Am J Health Syst Pharm. 1997;54:1833-6.
2. Pilbrant A, Cederberg C. Development of an oral formulation of omeprazole. Scand J Gastroenterol. 1985;108(suppl):113-20.
3. Berner B, John VA. Pharmacokinetic characterization of transdermal delivery systems. Clin Pharmacokinet. 1994;26:121-34.
4. Haas CE, Brazeau D, Cloen D, et al. Cytochrome P-450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. Eur J Clin Pharmacol. In press.
5. FDA/Center for Drug Evaluation and Research. Report: limited FDA survey of compounded drug products. Accessed at www.fda.gov/cder/pharmcomp/survey.htm, July 12, 2004.
6. Al-Achi, A, Greenwood R, Koo J. Need for quality-control testing of extemporaneously prepared oral solids. Am J Health Syst Pharm. 1996;53:1194-5.
7. Trissel LA. Compounding our problems-again. Am J Health Syst Pharm. 2003;60:432.
8. Allen LV. Contemporary pharmaceutical compounding. Ann Pharmacother. 2003;37:1526-8.
9. Kalia YN, Merino V, Guy RH. Transdermal drug delivery. Clinical aspects. Dermatol Clin. 1998;16:289-99.
10. Sastry MSP, Diwan PV. Comparative evaluation of orally and transdermally administered omeprazole against experimentally induced gastric ulcers in rats. Indian J Pharmacol. 1993;25:234-6.
11. Okamoto H, Yamashita F, Saito K, Hashida M. Analysis of drug penetration through the skin by the two-layer skin model. Pharm Res. 1989;6:931-7.
12. Potts RO, Guy RH. Predicting skin permeability. Pharm Res. 1992;9:663-9.
13. Cronin MTD, Dearden JC, Moss GP, Murray-Dickson G. Investigation of the mechanism of flux across human skin in vitro by quantitative structure-permeability relationships. Eur J Pharm Sci. 1999;7:325-30.
14. Moss GP, Cronin MTD. Quantitative structure-permeability relationships for percutaneous absorption: re-analysis of steroid data. Int J Pharm. 2002;238:105-9.
15. Li CJ, Obata Y, Higashiyama K, et al. Effect of 1-O-ethyl-3- butylcyclohexanol on the skin permeation of drugs with different physiochemical characteristics. Int J Pharm. 2003;259:193-8.
16. Lee CK, Uchida T, Kitagawa K, et al. Skin permeability of various drugs with different lipophilicity. J Pharm Sci. 1994;83:562-5.
17. Omeprazole Monograph. The Physical Properties Database (PHYSPROP). North Syracuse, N.Y.: Syracuse Research Corporation. Accessed at http://esc.syrres. com/interkow/webprop.exe?CAS=73590-58-6), August 20, 2004.
18. Song JC, Quercia RA, Fan C, et al. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am J Health Syst Pharm. 2001;58:689-94.
19. Marier J-F, Dubuc M-C, Drouin E, et al. Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease. Ther Drug Monit. 2004;26:3-8.